Enterprise Value
1.492B
Cash
318M
Avg Qtr Burn
N/A
Short % of Float
22.72%
Insider Ownership
1.50%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nucynta (tapentadol) Tablets / Extended-Release Tablets Details Pain, Acute pain | Approved Quarterly sales | |
Belbuca (Buprenorphine) Details Chronic pain | Approved Quarterly sales | |
Xtampza ER (oxycodone) Details Pain, Acute pain | Approved Quarterly sales | |
Approved Quarterly sales | ||
Symproic (naldemedine) Details Opioid induced constipation, Bowel preparation | Approved Quarterly sales |